ArQule Inc. (ARQL)

2.81
0.11 4.07
NASDAQ : Health Technology
Prev Close 2.70
Open 2.70
Day Low/High 2.70 / 2.86
52 Wk Low/High 0.92 / 3.35
Volume 476.98K
Avg Volume 799.90K
Exchange NASDAQ
Shares Outstanding 87.11M
Market Cap 235.20M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ArQule To Present Data At The 2018 American Association For Cancer Research (AACR) Annual Meeting

ArQule To Present Data At The 2018 American Association For Cancer Research (AACR) Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that pre-clinical and clinical data on the company's pipeline of drug candidates will be presented at the 2018 AACR Annual Meeting taking place in Chicago from April 14-April 18.

ArQule Reports Fourth Quarter And Full Year 2017 Financial Results

ArQule Reports Fourth Quarter And Full Year 2017 Financial Results

ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the fourth quarter and full year of 2017.

ArQule To Present At The 30th Annual Roth Conference On March 12, 2018

ArQule To Present At The 30th Annual Roth Conference On March 12, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, will present at the 30 th Annual Roth Conference on March 12 th, 2018, at 5:00 p.

ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018

ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter 2017 before the market opens on Monday, March 5, 2018.

ArQule To Present At The Leerink Partners 7th Annual Global Healthcare Conference On February 15, 2018

ArQule To Present At The Leerink Partners 7th Annual Global Healthcare Conference On February 15, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.

Roivant Sciences And ArQule Enter Into License Agreement For Derazantinib In China

Roivant Sciences And ArQule Enter Into License Agreement For Derazantinib In China

Roivant Sciences and ArQule, Inc. (NASDAQ: ARQL) today announced the initiation of a collaboration to pursue the development of derazantinib, a pan-FGFR (fibroblast growth factor receptor) inhibitor, in Greater China.

ArQule Announces Dosing In A Registrational Trial Of FGFR Inhibitor, Derazantinib, For Treatment Of Intrahepatic Cholangiocarcinoma

ArQule Announces Dosing In A Registrational Trial Of FGFR Inhibitor, Derazantinib, For Treatment Of Intrahepatic Cholangiocarcinoma

ArQule, Inc. (Nasdaq: ARQL) today announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib (ARQ 087) in FGFR2 fusion driven second-line intrahepatic Cholangiocarcinoma (iCCA).

ArQule Reports Third Quarter 2017 Financial Results

ArQule Reports Third Quarter 2017 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2017.

ArQule Announces $9.5 Million Private Placement Of Preferred Stock

ArQule Announces $9.5 Million Private Placement Of Preferred Stock

ArQule, Inc. (NASDAQ: ARQL) today announced the closing of a private placement with institutional investors led by The Pontifax Group pursuant to which the Company raised gross proceeds of $9.

FDA Grants Rare Pediatric Disease Designation To ArQule's Miransertib (ARQ 092) For The Treatment Of Proteus Syndrome

FDA Grants Rare Pediatric Disease Designation To ArQule's Miransertib (ARQ 092) For The Treatment Of Proteus Syndrome

ArQule, Inc. (Nasdaq: ARQL) today announced that the U.

ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017

ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2017 before the market opens on Thursday, November 9, 2017.

ArQule Announces $15.7 Million Private Placement Of Common Stock

ArQule Announces $15.7 Million Private Placement Of Common Stock

ArQule, Inc. (NASDAQ: ARQL) today announced the closing of a private placement with certain institutional investors, with leading participation by BVF Partners L.

ArQule To Present At The Cantor Fitzgerald Global Healthcare Conference On September 26, 2017

ArQule To Present At The Cantor Fitzgerald Global Healthcare Conference On September 26, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.

ArQule Reports Second Quarter 2017 Financial Results

ArQule Reports Second Quarter 2017 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2017.

ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017

ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter 2017 before the market opens on Friday, August 4, 2017.

ArQule Announces First Patient Dosed In Phase 1 Trial Of BTK Inhibitor, ARQ 531, For B-cell Malignancies

ArQule Announces First Patient Dosed In Phase 1 Trial Of BTK Inhibitor, ARQ 531, For B-cell Malignancies

ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a phase 1a/b trial with its BTK inhibitor, ARQ 531, in patients with B-cell malignancies refractory to other approved therapies.

ArQule Presents Preclinical Data For BTK Inhibitor, ARQ 531, At The 22nd Annual Congress Of The European Hematology Association (EHA)

ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models was presented at EHA Congress in Madrid, Spain.

ArQule Announces First Patient Dosed In Company Sponsored Phase 1/2 Trial Of AKT Inhibitor, ARQ 092, For Rare Overgrowth Diseases

ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a company sponsored phase 1/2 trial with its AKT inhibitor, ARQ 092, in patients with Overgrowth Diseases driven by genetic alterations of...

ArQule Presents Phase 1/2 Clinical Data With ARQ 087 In Intrahepatic Cholangiocarcinoma At The 2017 American Society Of Clinical Oncology (ASCO) Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that data from a phase 1/2 trial with fibroblast growth factor receptor (FGFR) inhibitor, ARQ 087, presented at ASCO demonstrate a meaningful clinical benefit to intrahepatic...

ArQule To Present Preclinical Data For BTK Inhibitor, ARQ 531, At The 22nd Annual Congress Of The European Hematology Association (EHA)

ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models will be presented on June 23, 2017 at EHA Congress in Madrid, Spain.

ArQule To Present Clinical Data At The 2017 American Society Of Clinical Oncology (ASCO) Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that data from the phase 1/2 trial in intrahepatic cholangiocarcinoma (iCCA) with fibroblast growth factor receptor (FGFR) inhibitor, ARQ 087, will be presented on June 3, 2017 at...

Arqule Reports First Quarter 2017 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter of 2017.

ArQule Announces Issuance Of U.S. Patent Covering Composition Of Matter Of Proprietary Reversible BTK Inhibitor, ARQ 531

ArQule, Inc. (Nasdaq: ARQL) today announced that the U.

ArQule To Report First Quarter 2017 Financial Results On May 3, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter 2017 before the market opens on Wednesday, May 3, 2017.

ArQule Receives Clearance Of Investigational New Drug Application From The FDA For Proprietary Reversible BTK Inhibitor, ARQ 531

ArQule, Inc. (Nasdaq: ARQL) today announced that it has received clearance from the U.

ArQule To Present At The 16th Annual Needham Healthcare Conference On April 4, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.

ArQule Announces Top-Line Results Of Phase 3 Clinical Study Of Tivantinib In Hepatocellular Carcinoma In Japan

ArQule, Inc. (Nasdaq: ARQL) today reported that its partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan, and that the trial did not meet its primary endpoint of...

ArQule Reports Fourth Quarter And Full Year 2016 Financial Results

ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the fourth quarter and full year of 2016.